ABP-201

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameABP-201
Drug Alias NameABP-201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsAngiopoietin-2 inhibitors
TargetsAngiopoietin-2Vascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesAbpro CorpMedimmune
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A